LHDX
Lucira Health, Inc. [LHDX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LHDX Stock Summary
In the News
LHDX Financial details
Company Rating
-
Market Cap
18.36M
Income
-143M
Revenue
212.13M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
221
Optionable
No
Shortable
Yes
Earnings
10 May 2023
P/E
-0.13
Forward P/E
-
PEG
-0.01
P/S
0.12
P/B
0.3
P/C
-
P/FCF
-0.2
Quick Ratio
0.71
Current Ratio
1.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.57
EPS next Y
-
EPS next Q
-
EPS this Y
78.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
31.53%
EPS Q/Q
483.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-72%
ROE
-90%
ROC
-1.26%
Gross Margin
-34%
Oper. Margin
-89%
Profit Margin
-90%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.108-4.35
52W High
-
52W Low
-
RSI
-
Rel Volume
1.69
Avg Volume
21.45M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
3.75954
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 21.45M
- Market Capitalization 18.36M
- Employee 221
- CEO Mr. Erik T. Engelson
- Headquarters EmeryVille,CA,US
- IPO Date 2021-02-04
-
Website
https://www.lucirahealth.com 
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
